Relationship between inflammatory markers, oxidant–antioxidant status and intima-media thickness in prepubertal children with juvenile idiopathic arthritis

Breda, Luciana; Marzio, D. Di; Giannini, Cosimo; Gaspari, Stefania; Nozzi, Manuela; Scarinci, A; Chiarelli, Francesco; Mohn, Angelika

doi:10.1007/s00392-012-0496-3

Cited by 49 publications

(42 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A combination therapy has been widely reported for JIA treatment (Tynjala et al 2011;Record et al 2011;Ramanan et al 2014), but no combination therapy with a biological product has been reported for the therapy of JIA yet. Oxidative stress was increased in JIA patients (Breda et al 2013;Lipinska et al 2015). On the other hand, JIA is the most common disease in pediatric rheumatology and characterized by chronically joint destruction and inflammation (Koos et al 2013;Abramowicz et al 2013).…”

Section: Discussionmentioning

confidence: 98%

Blueberry Improves the Therapeutic Effect of Etanercept on Patients with Juvenile Idiopathic Arthritis: Phase III Study

Zhong

Wang

Guo

et al. 2015

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

Juvenile idiopathic arthritis (JIA) is the most common arthritis in the adolescents under the age of 16. Etanercept, an inhibitor of tumor necrosis factor, is often used to treat JIA despite its significant side effects. Homeopathic remedies, such as blueberries, have anti-inflammatory properties with fewer unwanted effects and should be considered as a primary treatment. We aimed to explore the efficacy and safety of combination therapy of blueberry and etanercept for JIA. Two hundred and one JIA patients were selected, and randomly and evenly assigned to three groups: ETA (50 mg of etanercept twice weekly), ETABJ (matched etanercept and 50 ml blueberry juice daily) and ETAPJ (matched etanercept and placebo juice). The severity of JIA was measured using American College of Rheumatology scales (ACR) 20, 50 and 70. The levels of pro-inflammatory cytokines, interleukin-1 (IL1) alpha and IL1 beta, and interleukin-1 receptor antagonist (IL1RA) were measured by qRT-PCR and ELISA. After a 6-month follow-up, the ACR20, ACR50 and ACR70 in an ETABJ group were higher than those in other two groups (P < 0.05), suggesting clinically meaningful improvement in JIA. Meanwhile, the symptoms and side effects were reduced significantly or absent in an ETABJ group, including mental diseases, retrobulbar optic neuritis, gaining weight, infection, cutaneous vasculitis, diarrhea, uveitis and pancytopenia. Blueberries reduced the levels of IL1 alpha and beta, and increased the level of IL1RA. Thus, a combination therapy of blueberry and etanercept can reduce the severity of JIA and should be developed as a new method for JIA therapy.

show abstract

Section: Discussionmentioning

confidence: 98%

Blueberry Improves the Therapeutic Effect of Etanercept on Patients with Juvenile Idiopathic Arthritis: Phase III Study

Zhong

Wang

Guo

et al. 2015

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

show abstract

“…Studies on serum cholesterol levels in JIA have shown conflicting results, but these studies have mainly been done in children 17 36–39. There are no previous data on insulin resistance in JIA patients.…”

Section: Discussionmentioning

confidence: 99%

“…Vlahos et al 16 found impaired endothelial function in 30 children with JIA compared to controls, and Breda et al recently found an increased carotid intima media thickness in 38 JIA children compared to controls 17. Previous studies on BP in JIA have showed contradictory findings 16–19…”

Section: Introductionmentioning

confidence: 99%

Arterial haemodynamics and coronary artery calcification in adult patients with juvenile idiopathic arthritis

et al. 2014

View full text Add to dashboard Cite

show abstract

“…35 In a study performed in prepubertal children with JIA, it was found that children with JIA have, at baseline, higher levels of inflammatory markers (CRP and erythrocyte sedimentation rate), proinflammatory cytokines (including IL-1β and IL-6), total and LDL cholesterol, blood pressure, and carotid intima-media thickness when compared with healthy children. 36 Interestingly, all these elevated parameters were reversible with 1-year administration of nonsteroidal anti-inflammatory drugs and disease-modifying antirheumatic drugs. This suggests that not only does chronic, systemic inflammation result in premature development of atherosclerosis but also these changes are reversible with treatment of the inflammation.…”

Section: Alteration In Lipid Metabolismmentioning

confidence: 98%

Interleukin 1β

McCarty

Frishman

2014

Cardiology in Review

View full text Add to dashboard Cite

Interleukin 1β (IL-1β) is a proinflammatory cytokine that has been implicated in a number of rheumatologic and inflammatory conditions. The production and secretion of IL-1β from inflammatory cells is a tightly regulated process that has been extensively described and studied. In recent years, IL-1β has been associated with several steps in the development of atherosclerotic plaques, as well as other cardiovascular disease modifiers, such as cigarette smoking and type II diabetes mellitus. More recently, IL-1β has become the target of therapy in refractory rheumatologic conditions and is under investigation as a potential target of therapy in cardiovascular disease. The Canakinumab Anti-inflammatory Thrombosis Outcomes Study is currently underway and strives to use canakinumab, a monoclonal antibody directed against IL-1β, to evaluate the inflammatory hypothesis of cardiovascular disease. If the trial meets its primary end points (eg, significant reductions in nonfatal myocardial infarction, nonfatal stroke, and cardiovascular death), the Canakinumab Anti-inflammatory Thrombosis Outcomes Study will confirm the critical role of IL-1β-mediated inflammation in the development of cardiovascular disease and will introduce cytokine-directed therapy as a potential avenue for the treatment of atherosclerotic disease.

show abstract

Relationship between inflammatory markers, oxidant–antioxidant status and intima-media thickness in prepubertal children with juvenile idiopathic arthritis

Abstract: Chronic and systemic inflammation seems to lead to early atherosclerotic abnormalities even in pre-pubertal JIA children. Substantial improvement can be obtained with 1-year of appropriate therapy.

Cited by 49 publications

References 30 publications

Blueberry Improves the Therapeutic Effect of Etanercept on Patients with Juvenile Idiopathic Arthritis: Phase III Study

Blueberry Improves the Therapeutic Effect of Etanercept on Patients with Juvenile Idiopathic Arthritis: Phase III Study

Arterial haemodynamics and coronary artery calcification in adult patients with juvenile idiopathic arthritis

Interleukin 1β

Contact Info

Product

Resources

About